2025 Q3 -tulosraportti
41 päivää sitten36 min
Tarjoustasot
Määrä
Osto
500
Myynti
Määrä
100
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 27.3.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 5.11. | |
| 2025 Q2 -tulosraportti | 1.8. | |
| 2025 Q1 -tulosraportti | 9.5. | |
| 2024 Q4 -tulosraportti | 5.3. | |
| 2024 Q3 -tulosraportti | 8.11.2024 |
Datan lähde: FactSet, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·28.9.Latest positive news: 1. FDA clearance of IND amendment for OCU410ST (Stargardt disease, phase 2/3 study) FDA has approved Ocugen’s application to initiate the phase 2/3 pivotal trial for OCU410ST. 2. First patient dosed in GARDian3 (phase 2/3 for OCU410ST) Ocugen announced that the first patient has been dosed in their phase 2/3 study for OCU410ST.  3. EMA positive “scientific advice” — acceptance of one US-based trial for EU MAA EMA’s CHMP has given its approval that a single US clinical trial (OCU410ST) can form the basis for a MAA (Marketing Authorization Application) in Europe — which could save time and resources by not requiring additional European studies.  4. Binding term sheet for license for OCU400 in Korea Ocugen has entered into a binding term sheet agreement to license its modifying gene therapy OCU400 (for the treatment of retinitis pigmentosa) in Korea, with upfront payment and development milestones.  5. FDA Expanded Access Program (EAP) for OCU400 The FDA has approved that OCU400 can be given to some patients with retinitis pigmentosa outside of clinical trials through the EAP.  6. Health Canada: “No Objection Letter” for Phase 3 for OCU400 Health Canada has issued a “No Objection Letter” allowing the start of the Phase 3 liMeliGhT study for OCU400 in Canada in parallel with the US.  7. Previous news: Rare Pediatric Disease Designation for OCU410ST FDA has granted OCU410ST status as a “Rare Pediatric Disease,” which may bring regulatory incentives, such as priority review, etc.  8. Additional data on OCU410 (ArMaDa trial) – phase 1 results The business update mentions that OCU410 (for geographic atrophy / dry AMD) showed 23% slower lesion growth and 2-line gain in visual acuity in phase 1 without serious side effects.  9. Completed license agreement with Kwangdong (OCU400 in Korea) On September 15, 2025, Ocugen announced that the license agreement with Kwangdong for OCU400 has been completed, with an upfront payment of ~USD 7.5 million and additional milestone payments, etc.  Is now a good time to buy? From the latest news, there seem to be several positive regulatory and business steps that could generate investor interest. Specifically: • FDA clearance + dosing in phase 2/3 for OCU410ST is a significant clinical catalyst. • EMA's acceptance of a US trial for EU approval reduces some barriers in Europe. • Licensing agreements and access programs show that the company can start monetizing pipeline projects. However — even with these positive steps, we are still in early clinical phases. The risk of disappointing results, delays, dilution, etc. is still significant. If I were to assess: • I think it is close to an interesting purchase now – especially if you want to participate in the upward momentum and are willing to bear the risk. • However, I would divide the purchase into tranches to reduce the risk if something goes wrong.
·13.9.2024Will never amount to anything with that diving duck😖
·29.7.During the downturn you all said buy buy buy and now that it has had a chance to come up you are saying you should sell and take your loss and go. You yourself can start with that and hope that others will follow you.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
41 päivää sitten36 min
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·28.9.Latest positive news: 1. FDA clearance of IND amendment for OCU410ST (Stargardt disease, phase 2/3 study) FDA has approved Ocugen’s application to initiate the phase 2/3 pivotal trial for OCU410ST. 2. First patient dosed in GARDian3 (phase 2/3 for OCU410ST) Ocugen announced that the first patient has been dosed in their phase 2/3 study for OCU410ST.  3. EMA positive “scientific advice” — acceptance of one US-based trial for EU MAA EMA’s CHMP has given its approval that a single US clinical trial (OCU410ST) can form the basis for a MAA (Marketing Authorization Application) in Europe — which could save time and resources by not requiring additional European studies.  4. Binding term sheet for license for OCU400 in Korea Ocugen has entered into a binding term sheet agreement to license its modifying gene therapy OCU400 (for the treatment of retinitis pigmentosa) in Korea, with upfront payment and development milestones.  5. FDA Expanded Access Program (EAP) for OCU400 The FDA has approved that OCU400 can be given to some patients with retinitis pigmentosa outside of clinical trials through the EAP.  6. Health Canada: “No Objection Letter” for Phase 3 for OCU400 Health Canada has issued a “No Objection Letter” allowing the start of the Phase 3 liMeliGhT study for OCU400 in Canada in parallel with the US.  7. Previous news: Rare Pediatric Disease Designation for OCU410ST FDA has granted OCU410ST status as a “Rare Pediatric Disease,” which may bring regulatory incentives, such as priority review, etc.  8. Additional data on OCU410 (ArMaDa trial) – phase 1 results The business update mentions that OCU410 (for geographic atrophy / dry AMD) showed 23% slower lesion growth and 2-line gain in visual acuity in phase 1 without serious side effects.  9. Completed license agreement with Kwangdong (OCU400 in Korea) On September 15, 2025, Ocugen announced that the license agreement with Kwangdong for OCU400 has been completed, with an upfront payment of ~USD 7.5 million and additional milestone payments, etc.  Is now a good time to buy? From the latest news, there seem to be several positive regulatory and business steps that could generate investor interest. Specifically: • FDA clearance + dosing in phase 2/3 for OCU410ST is a significant clinical catalyst. • EMA's acceptance of a US trial for EU approval reduces some barriers in Europe. • Licensing agreements and access programs show that the company can start monetizing pipeline projects. However — even with these positive steps, we are still in early clinical phases. The risk of disappointing results, delays, dilution, etc. is still significant. If I were to assess: • I think it is close to an interesting purchase now – especially if you want to participate in the upward momentum and are willing to bear the risk. • However, I would divide the purchase into tranches to reduce the risk if something goes wrong.
- ·13.9.2024Will never amount to anything with that diving duck😖·29.7.During the downturn you all said buy buy buy and now that it has had a chance to come up you are saying you should sell and take your loss and go. You yourself can start with that and hope that others will follow you.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
500
Myynti
Määrä
100
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 27.3.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 5.11. | |
| 2025 Q2 -tulosraportti | 1.8. | |
| 2025 Q1 -tulosraportti | 9.5. | |
| 2024 Q4 -tulosraportti | 5.3. | |
| 2024 Q3 -tulosraportti | 8.11.2024 |
Datan lähde: FactSet, Quartr
2025 Q3 -tulosraportti
41 päivää sitten36 min
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 27.3.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 5.11. | |
| 2025 Q2 -tulosraportti | 1.8. | |
| 2025 Q1 -tulosraportti | 9.5. | |
| 2024 Q4 -tulosraportti | 5.3. | |
| 2024 Q3 -tulosraportti | 8.11.2024 |
Datan lähde: FactSet, Quartr
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·28.9.Latest positive news: 1. FDA clearance of IND amendment for OCU410ST (Stargardt disease, phase 2/3 study) FDA has approved Ocugen’s application to initiate the phase 2/3 pivotal trial for OCU410ST. 2. First patient dosed in GARDian3 (phase 2/3 for OCU410ST) Ocugen announced that the first patient has been dosed in their phase 2/3 study for OCU410ST.  3. EMA positive “scientific advice” — acceptance of one US-based trial for EU MAA EMA’s CHMP has given its approval that a single US clinical trial (OCU410ST) can form the basis for a MAA (Marketing Authorization Application) in Europe — which could save time and resources by not requiring additional European studies.  4. Binding term sheet for license for OCU400 in Korea Ocugen has entered into a binding term sheet agreement to license its modifying gene therapy OCU400 (for the treatment of retinitis pigmentosa) in Korea, with upfront payment and development milestones.  5. FDA Expanded Access Program (EAP) for OCU400 The FDA has approved that OCU400 can be given to some patients with retinitis pigmentosa outside of clinical trials through the EAP.  6. Health Canada: “No Objection Letter” for Phase 3 for OCU400 Health Canada has issued a “No Objection Letter” allowing the start of the Phase 3 liMeliGhT study for OCU400 in Canada in parallel with the US.  7. Previous news: Rare Pediatric Disease Designation for OCU410ST FDA has granted OCU410ST status as a “Rare Pediatric Disease,” which may bring regulatory incentives, such as priority review, etc.  8. Additional data on OCU410 (ArMaDa trial) – phase 1 results The business update mentions that OCU410 (for geographic atrophy / dry AMD) showed 23% slower lesion growth and 2-line gain in visual acuity in phase 1 without serious side effects.  9. Completed license agreement with Kwangdong (OCU400 in Korea) On September 15, 2025, Ocugen announced that the license agreement with Kwangdong for OCU400 has been completed, with an upfront payment of ~USD 7.5 million and additional milestone payments, etc.  Is now a good time to buy? From the latest news, there seem to be several positive regulatory and business steps that could generate investor interest. Specifically: • FDA clearance + dosing in phase 2/3 for OCU410ST is a significant clinical catalyst. • EMA's acceptance of a US trial for EU approval reduces some barriers in Europe. • Licensing agreements and access programs show that the company can start monetizing pipeline projects. However — even with these positive steps, we are still in early clinical phases. The risk of disappointing results, delays, dilution, etc. is still significant. If I were to assess: • I think it is close to an interesting purchase now – especially if you want to participate in the upward momentum and are willing to bear the risk. • However, I would divide the purchase into tranches to reduce the risk if something goes wrong.
- ·13.9.2024Will never amount to anything with that diving duck😖·29.7.During the downturn you all said buy buy buy and now that it has had a chance to come up you are saying you should sell and take your loss and go. You yourself can start with that and hope that others will follow you.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
500
Myynti
Määrä
100
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt